Drug Trial Radar · NCT07123454
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Sep 24, 2025
Primary completion
Jul 4, 2028
Study completion Feb 15, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Conditions
- B-cell Non-Hodgkin Lymphoma
Interventions
AZD4512Drug
AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion
SurovatamigDrug
Surovatamig (AZD0486) is a 'bispecific' antibody to be administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with dose-limiting toxicities (DLTs) during the DLT periodTime frame: Up to 4 weeks
- Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)Time frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
- Frequency of SAEs/AEs leading to discontinuation of study treatmentTime frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
- Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parametersTime frame: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Locations
23 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Irvine, California · Suspended
Research Site
Jacksonville, Florida · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
New York, New York · Suspended
Research Site
New York, New York · Recruiting
Research Site
Cleveland, Ohio · Withdrawn
Research Site
Myrtle Beach, South Carolina · Withdrawn
Research Site
Franklin, Tennessee · Recruiting
Research Site
Macquarie University, Australia · Not yet recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Guangzhou, China · Not yet recruiting
Research Site
Bologna, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Bunkyō City, Japan · Recruiting
Research Site
Kōtoku, Japan · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Taichung, Taiwan · Recruiting
Research Site
Taipei, Taiwan · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Newcastle upon Tyne, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.